

Luigi Bolondi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2884260/publications.pdf>

Version: 2024-02-01

66
papers

5,156
citations

201385

27
h-index

118652

62
g-index

67
all docs

67
docs citations

67
times ranked

7251
citing authors

#	ARTICLE	IF	CITATIONS
1	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016, 65, 727-733.	1.8	768
2	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	1.8	508
3	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2014, 111, 255-264.	2.9	480
4	Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , 2005, 42, 27-34.	3.6	410
5	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3361-3373.	1.4	375
6	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36.	3.4	342
7	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	5.1	285
8	Screening for hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 1076-1084.	1.8	196
9	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. <i>Hepatology</i> , 1999, 30, 58-64.	3.6	141
10	Triple Antiviral Therapy as a New Option for Patients With Interferon Nonresponsive Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 630-634.	3.6	141
11	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology</i> , The, 2017, 18, e101-e112.	5.1	123
12	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. <i>Gut</i> , 2018, 67, 1674-1682.	6.1	114
13	Primary gastric lymphoma versus gastric carcinoma: endoscopic US evaluation.. <i>Radiology</i> , 1987, 165, 821-826.	3.6	84
14	New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. <i>Digestive and Liver Disease</i> , 2007, 39, 187-195.	0.4	74
15	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 240-249.	1.4	70
16	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. <i>Digestive and Liver Disease</i> , 2015, 47, 518-522.	0.4	63
17	Clinical and diagnostic aspects of gluten related disorders. <i>World Journal of Clinical Cases</i> , 2015, 3, 275.	0.3	62
18	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , 2014, 46, 549-555.	0.4	57

#	ARTICLE	IF	CITATIONS
19	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. <i>Digestive and Liver Disease</i> , 2017, 49, 802-808.	0.4	51
20	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714.	2.0	51
21	Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 538-546.	1.9	49
22	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688.	0.4	49
23	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014, 32, 4006-4006.	0.8	38
24	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. <i>Hepatology</i> , 2000, 31, 349-357.	3.6	37
25	Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 2019, 119, 496-499.	1.8	37
26	Imaging of combined hepatocellular-choleangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 69-77.	1.6	31
27	Morphological and hemodynamic changes in the portal venous system after distal splenorenal shunt: An ultrasound and pulsed doppler study. <i>Hepatology</i> , 1988, 8, 652-657.	3.6	29
28	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. <i>Hepatology</i> , 2003, 34, 608-608.	3.6	27
29	A Relative Deficiency of Lysosomal Acid Lipase Activity Characterizes Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1134.	1.8	27
30	From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , 2011, 6, 93-98.	1.0	25
31	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. <i>Journal of Medical Virology</i> , 2000, 62, 25-28.	2.5	24
32	Liver transplantation for HCC. Treatment options on the waiting list. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 145-150.	1.9	24
33	Long term effects of gluten-free diet in non-celiac wheat sensitivity. <i>Clinical Nutrition</i> , 2019, 38, 357-363.	2.3	24
34	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018, 120, 95-102.	0.9	22
35	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.	1.4	22
36	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2015, 11, 3133-3142.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017, 262, 179-184.	0.4	19
38	Hepatocellular adenoma: An unsolved diagnostic enigma. <i>World Journal of Gastroenterology</i> , 2019, 25, 2442-2449.	1.4	19
39	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. <i>Liver Cancer</i> , 2017, 6, 337-348.	4.2	18
40	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465.	1.1	17
41	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017, 4, 129-137.	4.2	16
42	Regorafenib for the treatment of hepatocellular carcinoma. <i>Drugs of Today</i> , 2018, 54, 1.	0.7	15
43	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 119-136.	4.2	14
44	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2397-2407.	1.1	13
45	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , 2018, 72, 414-422.	1.6	13
46	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , 2010, 96, 1028-1030.	0.6	11
47	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. <i>Internal and Emergency Medicine</i> , 2016, 11, 19-30.	1.0	11
48	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
49	Effect of Potassium Canrenoate, an Anti-aldosterone Agent, on Incidence of Ascites and Variceal Progression in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1395-1402.	2.4	10
50	Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers. <i>Journal of Clinical Pathology</i> , 2016, 69, 102-108.	1.0	10
51	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 278-284.	1.9	10
52	Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. <i>Nutrients</i> , 2018, 10, 1940.	1.7	10
53	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 800-808.	1.1	8
54	Early Prediction of Treatment Response to Sorafenib with Elastasonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. <i>Ultraschall in Der Medizin</i> , 2013, 34, 541-549.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). Journal of Nephrology, 2021, 34, 77-88.	0.9	8
56	Intrahepatic artery pseudoaneurysm: A possible complication of blind thoracentesis. , 1999, 27, 151-155.		6
57	Contrast-enhanced ultrasound in liver cancer. Hepatic Oncology, 2015, 2, 51-62.	4.2	6
58	DAA's for HCV and risk of hepatocellular carcinoma: current standpoint. The Lancet Gastroenterology and Hepatology, 2018, 3, 736-738.	3.7	6
59	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2018, 36, 4088-4088.	0.8	6
60	Cytochemical detection of a class 3 aldehyde dehydrogenase in human hepatocellular carcinoma. Liver, 1995, 15, 87-92.	0.1	5
61	A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever. Case Reports in Hematology, 2019, 2019, 1-6.	0.3	3
62	Sudden change in the sonographic appearance of a thyroid cyst after percutaneous aspiration. Journal of Clinical Ultrasound, 1989, 17, 213-215.	0.4	1
63	Splanchnic arterial doppler parameters in portal hypertension. Hepatology, 1999, 29, 1610-1610.	3.6	1
64	Editorial: Cigarette smoking, abdominal blood flow and abdominal diseases. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 995-996.	1.4	0
65	Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis – Authors' reply. Lancet Oncology, The, 2017, 18, e193.	5.1	0
66	Improved sorafenib activity on hepatocellular carcinoma in Notch3 silenced in vivo and in vitro models.. Journal of Clinical Oncology, 2012, 30, 3061-3061.	0.8	0